The Past Suppression of Industry Knowledge of the Toxicity of Benzene to Humans and Potential Bias in Future Benzene Research

References

• Gennaro V, Tomatis L. Business bias: how epidemiological studies may underestimate or fail to detect increased risks of cancer and other diseases. Int J Occup Environ Health. 2005;11;356–9.
   PubMed Web of Science ®Google Scholar
• Michaels D, Monforton C, Lurie P. Selected science: an industry campaign to undermine an OSHA hexavalent chromium standard. Environ Health: A Global Access Scientific Source, 2006; 5: 5.
   PubMedGoogle Scholar
• Occupational Safety and Health Administration. Occupational Exposure to Hexavalent Chromium; Final Rule, February 28, Part II. Fed Reg. 2006; 71: 10099-385.
   Google Scholar
• Barrow CS, Conrad JVV Jr. Assessing the reliability and credibility of industry science and scientists. Environ Health Perspect. 2006; 114: 153–5.
   PubMed Web of Science ®Google Scholar
• Occupational Safety and Health Administration. Occupational Exposure to Benzene: Emergency Temporary Standards-Hearing, May 3, Part W. Fed Reg. 1977; 42: 22516–22529.
   Google Scholar
• Picciano D. Cytogenic study of workers exposed to benzene. Environ Res. 1979; 19: 33–8.
   PubMed Web of Science ®Google Scholar
• Daniel RL. Cytogenic study of workers exposed to benzene in the Texas Division of Dow Chemical U.S.A.; industrial hygiene data base. 1980. Unpublished manuscript submitted to OSHA by Venable JR, Director, U.S. Area Medical in response to request from OSHA staff.
   Google Scholar
• Infante PF, White MC. Benzene: epidemiologic observations of leukemia by cell type and adverse health effects associated with low-level exposure. Environ Health Perspect. 1983; 52: 75–82.
   PubMed Web of Science ®Google Scholar
• Occupational Safety and Health Administration. Occupational Exposure to Benzene: Fed Reg. 1978; 43: 5918-80.
   Google Scholar
• Infante PF, Biometry Section, IWS13, NIOSH, October 31, 1977. Letter inquiring about the status of the cytogenetic study results, to HC Scharnweber, Corporate Medical Director, Dow Chemical Company.
   Google Scholar
• Infante PF, Biometry Section, IWSB, NIOSH, January 4, 1978. Letter requesting cytogenetic study results or raw data, to D Picciano, Dow Chemical USA.
   Google Scholar
• Infante PF, Biometry Section, IWSB, NIOSH, January 17, 1978. Letter requesting cytogenetic study results, to E Blair, Director, Health and Environmental Research, Dow Chemical USA.
   Google Scholar
• Scharnweber HC, Corporate Medical Director, November 22, 1977. Letter stating the Dow cytogenetic study was still in progress due to incomplete benzene exposure determination, to PF Infante, Division of Surveillance, Hazard Evaluation and Field Studies, NIOSH.
   Google Scholar
• Picciano D, Occupational Health and Medical Research, Dow Chemical Company, January 10, 1978. Letter stating that cytogenetic study results must be cleared by E Blair of Dow Chemical, to PF Infante, Division of Surveillance, Hazard Evaluation and Field Studies, NIOSH.
   Google Scholar
• Holder BB, Director, Biomedical Research, Dow Chemical Company, March 1, 1978. Letter transmitting results of two cytogenetic studies, to PF Infante, Biometry Section, DSHEFS, NIOSH.
   Google Scholar
• Picciano D, Occupational Health and Medical Research, Dow Chemical Company, October 7, 1977. Internal memorandum recommending worker notification of cytogenetic study results and recommendations for medical and industrial hygiene measures to be taken, sent to BB Holder, Director, Biomedical research, Dow Chemical Company.
   Google Scholar
• Business Week. Research that clouds the benzene issue. June 26, 1978: 42–3.
   Google Scholar
• Occupational Safety and Health Administration. Occupational exposure to benzene: request for information, regulatory schedule. Fed Reg. 1983; 48: 31412–4.
   Google Scholar
• Occupational Safety and Health Administration. Occupational exposure to benzene; proposed rule and notice of hearing, Fed Reg. 1985; 50: 50512-86.
   Google Scholar
• Irons RD, Toxicologist, Chemical Industry Institute of Toxicology, May 23, 1984. Letter discussing progress of CIIT benzene cytogenetic study, to P Infante, Director, Office of Standards Review, OSHA.
   Google Scholar
• Infante PF, Director, Office of Standards Review, OSHA, November 9, 1984. Letter requesting cytogenetic study results, to AD Kligerman, Chemical Industry Institute of Toxicology.
   Google Scholar
• Neal RA, President, Chemical Industry Institute of Toxicology, November 14, 1984. Letter stating that slides for the rat portion of cytogenetic study are currently being reviewed, to PF Infante, Director, Office of Standards review, OSHA.
   Google Scholar
• Vance EL, Director, Health Standards Program, OSHA, Feb 5, 1985. Letter stating that OSHA has been informed by EPA that the CIIT benzene cytogenetic study demonstrates dose-related effects at 1 ppm and requesting the results from CIIT, to RA Neal, President, Chemical Industry Institute of Toxicology.
   Google Scholar
• Neal RA, President, Chemical Industry Institute of Toxicology, February 13, 1985. Letter stating the reading of the slides related to cytogenetic findings in rats have just been completed, to RL Vance, Director, Health Standards Program, OSHA.
   Google Scholar
• Neal RA, Director, Chemical Industry Institute of Toxicology, June 7, 1985. Letter transmitting CIIT cytogenetic study results, to EL Vance, Director, Health Standards Programs, OSHA.
   Google Scholar
• Durham Morning Herald. Park lab denies delaying results of benzene tests. June 6, 1985.
   Google Scholar
• Kover FD, Chief, Chemical Screening Branch, EPA, February 6, 1985. Letter stating EPA has been informed of adverse cytoge-netic effects in rats exposed to 1 ppm benzene and higher in the CIIT study, to PF Infante, Director, Office of Standards Review, OSHA.
   Google Scholar
• Kusnetz HL, Manager, Safety and Industrial Hygiene, Shell Oil Company, July 28, 1983. Letter transmitting initial mortality study results of Wood River and Deer Park facilities, to T Auchter, Director, OSHA.
   Google Scholar
• Austin WB, Phillips CF. Development and implementation of a health surveillance system. Am Indust Hyg Assoc J. 1983; 44: 638–42.
   PubMed Web of Science ®Google Scholar
• Infante PF, Director, Office of Standards Review, OSHA, January 27, 1984. Letter requesting data for blood abnormalities among benzene exposed workers, to Howard L. Kusnetz, Man-ager, Safety and Industrial Hygiene, Shell Oil Company.
   Google Scholar
• Infante PF, Director, Office of Standards Review, OSHA, Febru-ary 22, 1984. Letter requesting data for blood abnormalities among benzene-exposed workers, to RE Joyner, Director, Corporate Medical Department, Shell Oil Company.
   Google Scholar
• Joyner RE, Director, Corporate Medical Department, Shell Oil Company, February 13, 1984. Letter stating no employee meet-ing benzene exposure criteria had a blood abnormality, to PF Infante, Director, Office of Standards Review, OSHA.
   Google Scholar
• Joyner RE, Director, Corporate Medical Department, Shell Oil Company, March 5, 1984. Letter asking OSHA to redefine its criteria in requesting data related to blood abnormalities, to PF Infante, Director, Office of Standards Review, OSHA.
   Google Scholar
• Kusnetz HL, Manager, Safety and Industrial Hygiene, Shell Oil Company, March 5, 1984. Letter asking OSHA Director to alle-viate Shell Oil Company from benzene data requests by Dr. Infante, to T Auchter, Director, OSHA.
   Google Scholar
• Infante PF, Director, Office of Standards Review, OSHA. April 17, 1984. Letter requesting data for blood abnormalities among benzene-exposed workers, to RE Joyner and HL Kusnetz, Corporate Medical Department, Shell Oil Company.
   Google Scholar
• Joyner RE, Kusnetz HL, Corporate Medical Director, and Man-ager, Safety and Industrial Hygiene, Shell Oil Company, May 17, 1984. Letter providing data for Shell benzene-exposed workers with blood abnormalities, to PF Infante, Director, Office of Standards Review, OSHA.
   Google Scholar
• Kusnetz HL. President's Page; August Potpourri. Am Indust Hyg Assoc” 1985; 46: A4.
   PubMedGoogle Scholar
• Rinsky RA, Smith AB, Hornung R, et al. Benzene and leukemia: an epidemiologic risk assessment. N Engl J Med. 1987;316:1044 50.
   Google Scholar
• Occupational Safety and Health Administration. Occupational Exposure to Benzene: Final Rule, September 11, Part II. Fed Reg. 1987; 52: 34460-578.
   Google Scholar
• Hayes RB, Yin SN, Dosemeci M, Li GL, Wacholder S, Travis LB, et al. Benzene and the dose-related incidence of hematologic neoplasms in China. Chinese Academy of Preventive Medi-cine-National Cancer Institute Benzene Study Group. J Natl Cancer Inst. 1997;89,1065–71.
   PubMed Web of Science ®Google Scholar
• Lan Q Zhang L, Li G, et al. Hematotoxicity in workers exposed to low levels of benzene. Science. 2004; 306: 1774–6.
   Google Scholar
• Qu Q Shore R, Li G, et al. Hematological changes among Chi-nese workers with a broad range of benzene exposures. Am J Ind Med. 2002; 42: 275–85.
   PubMed Web of Science ®Google Scholar
• Wong O. A critique of the exposure assessment in the epidemi-ologic study of benzene-exposed workers in China conducted by the Chinese Academy of Preventive Medicine and the US National Cancer Institute. Regul Toxicol Pharmacol. 1999; 30: 259–67.
   PubMed Web of Science ®Google Scholar
• Budinsky RA, DeMott RP, Wernke MJ, Schell JD. An evaluation of modeled benzene exposure and dose estimates published in the Chinese-National Cancer Institute collaborative epidemiology studies. Regul Toxicol Pharmacol. 1999; 30: 244–58.
   PubMed Web of Science ®Google Scholar
• Hayes RB, Songnian Y, Dosemeci M, Linet M. Benzene and lym-phohematopoietic malignancies in humans. Am J Ind Med. 2001; 40: 117–26.
   PubMed Web of Science ®Google Scholar
• Cappiello D. Oil industry funding study to contradict cancer claims. Houston Chronicle. April 29, 2005.
   Google Scholar
• Mehlman MA, Adjunct Professor, Robert Wood Johnson Schoolof Medicine, June 29 and 30, 2005. Letter requesting the companies that are funding the API benzene research in Shanghai to transfer the research to an independent body, to D O'Reilly, Chairman of the Board and CEO, Chevron Texaco Corp, J Hofmeister, President, Shell Oil Co, US, LE Raymond, Chairman and CEO, Exxon Mobil Chemical Co., and President and CEO, British Petroleum Co., UK.
   Google Scholar